ライフサイエンスコーパス: inhibitor

1 hdrawal of the stress condition and the PI3K inhibitor.

2 olecule that is used worldwide as a protease inhibitor.

3 ses, which were reduced by the benzimidazole inhibitor.

4 proteins, which was blocked by a Rho-kinase inhibitor.

5 lantation and/or treatment with a proteasome inhibitor.

6 as suppressed upon the treatment of the mTOR inhibitor.

7 ed differential patterns in response to each inhibitor.

8 a novel reverse transcriptase-translocation inhibitor.

9 d optimization of cysteine-targeted covalent inhibitors.

10 rs a therapeutic vulnerability to glycolytic inhibitors.

11 ng, and the pioneer generation of true hsTYR inhibitors.

12 ferences in affinities toward potential CRM1 inhibitors.

13 ncluding for widely used standard tyrosinase inhibitors.

14 development of valuable colistin resistance inhibitors.

15 st are also resistant to eradication by PI3K inhibitors.

16 king the effects of matrix metalloproteinase inhibitors.

17 -2-hydroxybenzamide analogues as potent HAdV inhibitors.

18 ered them more susceptible toward glycolytic inhibitors.

19 , including the development of BTK and CXCR4 inhibitors.

20 aminase, dual TORC1/2, or programmed death-1 inhibitors.

21 70 are two structurally related USP14/UCH-37 inhibitors.

22 optimization of this novel class of survivin inhibitors.

23 uate response to tumor necrosis factor (TNF) inhibitors.

24 o understand the clinical relevance of these inhibitors.

25 mechanistic hypotheses for newly discovered inhibitors.

26 of novel monophosphonate small-molecule CD73 inhibitors.

27 checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors.

28 ay augment the activity of immune checkpoint inhibitors.

29 stability of three series of urea-based sEH inhibitors.

30 of antibodies to their unique properties as inhibitors.

31 usly cytotoxic properties attributed to HDAC inhibitors.

32 al risk factor in patients treated with RAAS inhibitors.

33 classification of resistance to HIV protease inhibitors.

34 sminogen activator and plasminogen activator inhibitor-1, was depressed by exposure to high glucose,

35 Peptidase inhibitor 3 (PI3), a gene in the antimicrobial peptide p

36 tudies, we also identified a dual AIG1/ADTRP inhibitor, ABD-110207, which is active in vivo Acute tre

37 compare downstream and upstream oral P2Y(12) inhibitors administration strategies in patients with no

38 superior for patients receiving aggregation inhibitors after LT.

39 of a KV1.3 channel blocker or a glutaminase inhibitor ameliorated disability in experimental neuroin

40 (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in com

41 It is plausible that the ACE inhibitors and ACE receptor blockers may have the potent

42 ear, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

43 ring agents - sodium-glucose cotransporter 2 inhibitors and incretin therapies - has markedly changed

44 cer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TA

45 ) factors active in the S/G2 phase as potent inhibitors and regulators of L1 activity.

46 e way for the development of allosteric HDAC inhibitors and regulators to improve the therapy for sev

47 ination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo a

48 er efficiency and selectivity, the effect of inhibitors, and density functional theory (DFT) calculat

49 s, building in silico models to characterize inhibitors, and leveraging real-world data from electron

50 ecause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists i

51 ontrast, patient age, the use of proton pump inhibitors, and the use of primary prophylaxis were not

52 Although checkpoint inhibitors are already used as therapy against various c

53 While distinct BET inhibitors are being pursued as therapies in oncology, a

54 Targeted covalent inhibitors are currently showing great promise for syste

55 l repertoire diversity.IMPORTANCE Checkpoint inhibitors are effective immunotherapeutics to restore c

56 n attractive target for antibiotics and many inhibitors are in clinical development.

57 Checkpoint inhibitors are now frequently used for oncologic conditi

58 Accordingly, HER2 blockers, but not c-MET inhibitors, are paradoxically effective at restraining i

59 channels and the potential for Orai1 channel inhibitors as inotropic therapies for maintaining contra

60 Weak-AIDA-NMR finds true inhibitors, as opposed to only binders to the target pro

61 with an increased risk of immune checkpoint inhibitor-associated AKI.

62 an be accomplished with a single dose of p53 inhibitor at the commencement of BRAF/MEK inhibitor ther

63 Of note, pretreatment with an HBV entry inhibitor attenuated the TLR2-mediated response to HBV,

64 Here we design small peptidic inhibitors based on the atomic structure of the core of

65 tent, highly selective, orally available ATR inhibitor BAY 1895344, which exhibited strong monotherap

66 Consistent with this, the IkappaB kinase inhibitor BAY11-7085 and dominant-negative mutant Ikappa

67 To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding gro

68 ture of PYCR1 complexed with NFLP shows that inhibitor binding is accompanied by conformational chang

69 A PI3K inhibitor, BKM120, was tested in our patient-derived xen

70 Pretreatment with a glucocorticoid synthesis inhibitor blocked the memory enhancement as well as the

71 -1 sensitized to poly(ADP-ribose) polymerase inhibitors both in vitro and ex vivo These findings migh

72 roughput in vitro primary screen to identify inhibitors, building in silico models to characterize in

73 rated by experiments using the specific NKCC inhibitor bumetanide.

74 Moreover, the DNA topoisomerase-1 inhibitor camptothecin (CPT) down-regulated FLIP in panc

75 Ultraselective HDAC6 inhibitors can reduce tumor growth and invasiveness of b

76 reviously demonstrated that copper dependent inhibitors (CDIs), a class of antibiotics that are only

77 hioxotriazinoindole scaffold of the novel AR inhibitor cemtirestat by replacement of sulfur with oxyg

78 his, administration of a fatty acid synthase inhibitor, cerulenin, also alleviated the pathology of p

79 atment with an autophagosome-lysosome fusion inhibitor, chloroquine, indicating that Rab27b KD induce

80 ha-1 antitrypsin, SERPINA1 (serpin peptidase inhibitor, clade A, member 1), in determining chronic ob

81 Finally, a bortezomib (BTZ)/MEK inhibitor combination showed enhanced activity in vivo s

82 ticularly for new beta-lactam/beta-lactamase inhibitor combinations.

83 scribe the development of a pan-RAS biologic inhibitor composed of the RAS-RAP1-specific endopeptidas

84 indicate that Sarm1 and/or specific calpain inhibitors could be developed to prevent cisplatin induc

85 This repurposing of existing kinase inhibitors could lay the foundation for alternative infe

86 nti-angiogenic agents, EGFR inhibitors, mTOR inhibitors, CTLA-4 inhibitors, or PD-1/PD-L1 inhibitors,

87 ntestinal organoids incubated with the Notch inhibitor DAPT, intestine tissues from mice given inject

88 These heterodimeric tryptase inhibitors demonstrate superior activity compared to mon

89 These BRD4 BD1 inhibitors demonstrated impressive in vivo efficacy and

90 ibitors was achieved through structure-based inhibitor design.

91 gimens that do not contain a tyrosine-kinase inhibitor, despite the use of high-risk chemotherapy reg

92 Atabecestat is an orally administered BACE inhibitor developed to treat Alzheimer's disease.

93 cautiously optimistic, as the field of MAGL inhibitor development transitions from preclinical to cl

94 ced BC after resistance to TAM and aromatase inhibitors develops.

95 mice given injections of the gamma-secretase inhibitor dibenzazepine, and mice with intestine-specifi

96 the slow H(2)S releaser GYY3147 and the CSE inhibitor DL-propargylglycine demonstrated that H(2)S is

97 how substitutions in this position modulate inhibitor efficiency and substrate specificity leading t

98 trate dehydrogenase 2 (IDH2) mutant-specific inhibitor enasidenib, leading to improved quality of lif

99 elanoma to chemotherapy or immune checkpoint inhibitors, encouraging results have been reported with

100 inhibitors, CTLA-4 inhibitors, or PD-1/PD-L1 inhibitors, etc.

101 J female mice treated with the benzimidazole inhibitor exhibited a significant reduction of pristane-

102 C-targeting drugs are nonselective, pan-HDAC inhibitors, exhibiting adverse side effects at therapeut

103 s of oral administration of a small molecule inhibitor for CCR2, CCR2i, which blocks CCR2-mediated ch

104 aries (DELs) have enabled discovery of novel inhibitors for many distinct protein targets of therapeu

105 systemically administered epigenetic enzyme inhibitors for relapse prevention in human drug users.

106 ovided a proof of concept for application as inhibitors for the protein methyltransferase target PRMT

107 evelopments toward more potent and selective inhibitors for the tumor-expressed CA IX.

108 identification of new drug targets and their inhibitors for visceral leishmaniasis.

109 additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease a

110 A potent trypsin inhibitor from Tityus obscurus scorpion venom was charac

111 identified several candidate RAN translation inhibitors from a high-throughput small-molecule screen

112 a prospective context, nearly all candidate inhibitors from a screen against acetylcholinesterase sh

113 ith a CXCR4 antagonist (AMD3100) or hedgehog inhibitor (GDC-0449) displays reduced tumor growth.

114 The potent HIV-1 capsid inhibitor GS-6207 is an investigational principal compon

115 Treatment with the CSF1R inhibitor GW2580 significantly attenuated MPTP-induced C

116 Recently, a peptidomimetic inhibitor has entered clinical trial; however, small-mol

117 round therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovasc

118 We demonstrate that all four PARP inhibitors have a unique polypharmacological profile acr

119 Several of these inhibitors have advanced to clinical trials, both singly

120 Many peptide inhibitors have been constructed from the various segmen

121 inflammation, and small-molecule ERK5 kinase inhibitors have been developed.

122 Few LsrK inhibitors have been reported so far, allowing ample roo

123 SGLT2 (sodium-glucose cotransporter 2) inhibitors have been shown to lower blood pressure, redu

124 ures can lead to human disease, and how PARP inhibitors have emerged as a novel clinical therapy to t

125 In clinical use, JAK inhibitors have mixed effects on the overall disease bur

126 Small-molecule kinase inhibitors have the potential for broad efficacy, conven

127 ta suggest that acetyl-CoA carboxylase (ACC) inhibitors have the potential to rebalance disordered li

128 Pharmacologic HIF hydroxylase inhibitors (HIs) are effective for the treatment of anem

129 here the creation of a uniquely acting HSP70 inhibitor (HSP70i) that targets multiple compartments in

130 Immune checkpoint inhibitor (ICI) therapy is often accompanied by immune-r

131 Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in

132 Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by e

133 s in patients treated with immune checkpoint inhibitors (ICIs).

134 stemic administration of acetazolamide, a CA inhibitor, immediately after the extinction session dose

135 come trials in patients with diabetes, SGLT2 inhibitors improve cardiovascular and renal outcomes, in

136 Likewise, the MLK3 inhibitor in pan T cells, isolated from breast cancer pa

137 ssed the application of HBPs as viral uptake inhibitors in COVID-19 and explained possible mechanisms

138 Treatment with TNF inhibitors in RA patients reverses the expression change

139 s of treatment with renin-angiotensin system inhibitors in SARS-CoV-2 may outweigh the risks and at t

140 ns the failure of potent biotin biosynthesis inhibitors in standard mouse infection models.

141 Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With Elevated Risk).

142 We identified 14 potent Nape-pld inhibitors in the Spectrum Collection, with the two most

143 current interest surrounding the use of LSD1 inhibitors in the treatment of multiple different malign

144 Treatment of both patients' cells with JAK inhibitors in vitro reduced phosphorylated STAT1 to norm

145 (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillat

146 efficacy and safety of ixekizumab, an IL-17 inhibitor, in non-radiographic axial spondyloarthritis.

147 h zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM.

148 ion of Pyk2 and treatment with a Pyk2 kinase inhibitor increased viral DNA content in keratinocytes t

149 sis per se, nor did it protect from PAN-PDE4 inhibitor-induced gastroparesis, indicating that gastric

150 nt initiation with integrase strand transfer inhibitors (INSTIs) has been associated with excess weig

151 This PCSK9 inhibitor is one of many peptides that could benefit fro

152 e key challenge in generating antibody-based inhibitors is the lack of fundamental information relati

153 ides, which present the most potent V-ATPase inhibitors known to date.

154 ween low circulating plasma serine peptidase inhibitor Kunitz type-1 (SPINT1) concentrations at 36 we

155 geted treatment with the small-molecule ERBB inhibitor lapatinib led to prolonged clinical benefit an

156 oliferate in the presence of the HER2 kinase inhibitor lapatinib.

157 with apolipoprotein A1, anti-CD15, and a SHH inhibitor (LDE225).

158 yme cleaved the tripeptide aldehyde protease inhibitors, leading to the formation of "pro-pyrazinones

159 tein ligand-1 (PSGL-1)-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free d

160 roprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipopro

161 /-) BMDN or pretreatment of BMDN with TREM-1 inhibitor LP17 significantly decreased the frequency of

162 in vivo activity for the biotin biosynthesis inhibitor MAC13772.

163 This study demonstrates that MEKi plus MET inhibitor may delay or prevent a novel mechanism of acqu

164 next found that the AKT Ser/Thr kinase (AKT) inhibitor MK2206 blocks the starvation-dependent increas

165 to 3 months after PCI with continued P2Y(12) inhibitor monotherapy compared with traditional dual ant

166 onth DAPT, short-term DAPT followed by P2Y12 inhibitor monotherapy reduces major bleeding after percu

167 Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug r

168 F inhibitors or anti-angiogenic agents, EGFR inhibitors, mTOR inhibitors, CTLA-4 inhibitors, or PD-1/

169 It is commonly believed that mTOR inhibitors (mTORi) should not be used in high-immunologi

170 ed or reversed after treatment with the DDR1 inhibitor, nilotinib.

171 leukemia (CLL) include venetoclax, the oral inhibitor of B-cell lymphoma-2, and inhibitors of kinase

172 all, the hC3Nb3 nanobody represents a potent inhibitor of both the alternative pathway and the termin

173 hieved using B4Crry, an injury site-targeted inhibitor of C3 activation.

174 was further confirmed using a small-molecule inhibitor of ferroptosis that prevents CZ-induced loss o

175 ith serum-glucocorticoid kinase 1 (SGK1), an inhibitor of glycogen synthase kinase 3beta, as part of

176 Consistent with this, 2-deoxyglucose, an inhibitor of glycolysis, augmented AMPK activity and att

177 e show that the microcephalin 1/BRCT-repeats inhibitor of hTERT (MCPH1/BRIT1) protein, mutated in pri

178 ion of GW296115 has confirmed it as a potent inhibitor of kinases including BRSK1 and BRSK2 that were

179 ation, sacubitril/valsartan decreased tissue inhibitor of matrix metalloproteinase 1 by 8% (95% confi

180 12 hours after admission, and urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth

181 ective response, whereas Keap1-an endogenous inhibitor of Nrf2 signaling-dampens these protective res

182 ropathy rat model treated with amiloride, an inhibitor of plasminogen activation, and measured change

183 bumin, the potency of JMS-053 as an in vitro inhibitor of PTP4A3 and human A2780 ovarian cancer cell

184 APIO-EE-07, a novel dual-target inhibitor of RSK1 and MSK2, can suppress the growth of c

185 , by identifying let-7i-3p miRNA as a strong inhibitor of Salmonella replication and performing in-de

186 scovery of IACS-13909 as a potent, selective inhibitor of SHP2 with drug-like properties, and targeti

187 cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not be

188 screening identified doxorubicin (DXR) as an inhibitor of the Akt-beta-catenin interaction at low dos

189 potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.

190 Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1

191 8 and in mice given MCC950, a small molecule inhibitor of the NLRP3-inflammasome.

192 Baloxavir is a cap-dependent inhibitor of the polymerase acid (PA) protein of influen

193 Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and

194 generate an action potential through PAR(2) Inhibitors of adenylyl cyclase and protein kinase A (PKA

195 abilize MYCN protein, such as small-molecule inhibitors of Aurora A and mTOR, are currently being eva

196 (3A) and the chaperone protein resistance to inhibitors of choline esterase (RIC-3).

197 synthesized in this study are highly potent inhibitors of DHODH in an enzymatic assay, while also in

198 n principle for synthesizing abiotic polymer inhibitors of enzymes.

199 des are suitable for further optimization as inhibitors of filovirus entry, with the potential to be

200 on of a class of potent, orally bioavailable inhibitors of glucose transporters, targeting both GLUT1

201 We identified seven previously unknown inhibitors of GMII from a library of over 350 iminosugar

202 ilitate the identification of novel GSK3beta inhibitors of high potency and specificity.

203 a; these effects of IL22 were prevented with inhibitors of Janus kinase signaling to signal transduce

204 the oral inhibitor of B-cell lymphoma-2, and inhibitors of kinases in the B-cell receptor signaling p

205 ctive and largely resistant to physiological inhibitors of LPL.

206 Synergy between inhibitors of matrix metalloproteases and TMPRSS2 sugges

207 compounds as active site-directed reversible inhibitors of mPTPB.

208 acropinocytosis was confirmed using specific inhibitors of PI3K and actin polymerization.

209 Studies using inhibitors of PPARbeta/delta or sirtuin-1 showed that th

210 In the current study, we report that inhibitors of the DNA damage response kinase ATR can sig

211 Stoichiometric inhibitors often function as molecular decoys of protein

212 This effect of mTORC1/2 inhibitors on protein synthesis and RRM2 levels was resc

213 mice were treated with the immunoproteasome inhibitor ONX 0914.

214 pport stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients

215 according to their mechanism of action: VEGF inhibitors or anti-angiogenic agents, EGFR inhibitors, m

216 Inhibition of USP7 and USP10 by chemical inhibitors or knockdown had an additive effect on NHE3.

217 ts, EGFR inhibitors, mTOR inhibitors, CTLA-4 inhibitors, or PD-1/PD-L1 inhibitors, etc.

218 m a small-molecule screen, identify the mTOR inhibitors OSI-027, AZD2014 and AZD8055.

219 reased sensitivity to the OGT small molecule inhibitor OSMI-1.

220 Several studies reported that the CDK inhibitor p27(Kip1) promotes starvation-induced autophag

221 Treating AML cells with an EZH2 inhibitor partially restored the expression of approxima

222 The conformationally constrained HDAC8 inhibitors present an alternative biological probe for f

223 emonstrate that allosteric but not catalytic inhibitors prevent the chromatin assembly of functional

224 ystemic application of NS8593, a known TRPM7 inhibitor, prevents kidney atrophy in UUO kidneys, retai

225 ission electron microscopy verified that PIM inhibitors promote mitochondrial fission and apoptosis i

226 antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregna

227 Here we repurposed DXR as a targeted inhibitor rather than a broadly cytotoxic chemotherapy.

228 Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalizat

229 Sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end

230 efficacy of PCCs in patients with factor Xa inhibitor-related ICH are needed.

231 results from clinical trials of various AKT inhibitors remain suboptimal, suggesting that AKT-driven

232 ylethanolamides-lipoprotein-borne Hh pathway inhibitors required for Smo destabilization.

233 E5, which can be exploited using the HPV E5 inhibitor rimantadine to improve outcomes for head and n

234 o evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irr

235 vascular outcome study investigating the BET inhibitor RVX-208 (now called apabetalone) has already b

236 hat newly introduced nitrogen atoms into the inhibitor scaffold can act as hydrogen bond acceptor sit

237 t with lovastatin, a mevalonate biosynthesis inhibitor, selectively inhibited protein prenylation and

238 LZ and would be useful for treatment of PARP inhibitor-sensitive cancers in which oral medications ar

239 failed to mount a reverse transcriptase (RT) inhibitor-sensitive immune response following HIV-1 infe

240 the underlying genetic determinants of CHK1 inhibitor sensitivity remain unclear.

241 Genetic ablation of serine protease inhibitor SerpinB9 (Sb9) results in the death of tumor c

242 The Published Kinase Inhibitor Set (PKIS) is a publicly-available chemogenomi

243 Ruxolitinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therap

244 Dose response curves of ML385, an NRF2 inhibitor, showed that ischemia induces addiction to NRF

245 , SphK1 inhibition with the isotype-specific inhibitor SK1-I in WT cells induced accumulation of chol

246 Consistently, expression of the germination inhibitor SOMNUS, induced by ABI3 and PIF1, is upregulat

247 s, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT.

248 ants, including selective serotonin reuptake inhibitors (SSRIs), initiate their drug actions by rapid

249 Despite the abundant presence of HDAC inhibitors such as butyrate in the intestine, we found t

250 anti-tumor immune responses using checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors.

251 own whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase in

252 rged as an important therapeutic target with inhibitors targeting its methyltransferase activity unde

253 This study aimed to discover small-molecule inhibitors targeting RANKL trimer formation.

254 Meanwhile, OOPC acts as inhibitor that "kills" PLA2 upon enzymatic attack.

255 vo PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibition in vivo.

256 his Perspective is focused on beta-lactamase inhibitors that disable the most prevalent cause of anti

257 with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC i

258 cer is found in the use of immune checkpoint inhibitor therapeutics.

259 ant association between the duration of mTOR inhibitor therapy and psoas muscle area on multiple line

260 ion and to assess the efficacy of a protease inhibitor therapy targeting neutrophil elastase for the

261 bitor use, and combination immune checkpoint inhibitor therapy were each independently associated wit

262 53 inhibitor at the commencement of BRAF/MEK inhibitor therapy.

263 rase 1 (PARP1)-DNA complexes trapped by PARP inhibitors, thereby promoting cell survival after drug t

264 n with the current FDA approval for two FLT3 inhibitors, these modalities were unable to cure AML or

265 red the safety and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy.

266 esis in the presence of an androgen receptor inhibitor to the extent seen in ED peptide-treated femal

267 rtant first step in repurposing class I PI3K inhibitors to modulate CMA in vivo.

268 These assays often use elongation inhibitors to purportedly inhibit the release of puromyc

269 Future development of DHHC20 inhibitors to reduce EGFR-PI3K signaling could be benefi

270 rotein, we evaluated the ability of protease inhibitors to suppress S glycoprotein function.

271 signaling; however, the clinical efficacy of inhibitors to this pathway is limited by resistance.

272 colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density.

273 Here, we use the clinically approved MEK inhibitor Trametinib to investigate its potential use in

274 SCs) cultured with MEK/ERK and GSK3beta (2i) inhibitors transition to ground state pluripotency.

275 CMV) infection, it was shown that checkpoint inhibitor treatment increased T cell proliferation and f

276 used wild-type mice treated with the SULT1E1 inhibitor triclosan to determine the effect of pharmacol

277 Rationale: The role of PI (protease inhibitor) type Z heterozygotes and additional rare vari

278 pment of knockout mouse models and molecular inhibitors unique to necroptotic proteins, this cell dea

279 AML cells with quizartinib, a selective FLT3 inhibitor, upregulates inflammatory genes in DTPs and th

280 Lower baseline eGFR, proton pump inhibitor use, and combination immune checkpoint inhibit

281 ective, the specificity and mechanism of the inhibitor used is controversial.

282 Recent developments include SGLT2 inhibitors, vericiguat, and transcatheter mitral valve r

283 (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist p

284 The most potent inhibitor was NFLP, which had a competitive (with P5C) i

285 on of the cysteine-rich Bowman-Birk protease inhibitor was several fold higher in transgenic soybean

286 A series of first-generation bifunctional inhibitors was achieved through structure-based inhibito

287 A series of pyrazolopyrimidine-based inhibitors was developed with a vector in the 2-position

288 brocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults wi

289 sport studies) and JPH-203 (a specific LAT-1 inhibitor), we showed that the efflux agonist did not in

290 Using this inhibitor, we explored the enzymatic function of TET pro

291 s potency compares well with established MIF inhibitors, whereas msR4M-L1 does not interfere with car

292 hows that Ponatinib and BRAF dimer selective inhibitors will be useful in treating BRAF-dependent tum

293 Modification of the inhibitor with a cell-penetrating entity yielded a cell-

294 a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia

295 y that couples an allosteric, reversible PTP inhibitor with an E3 ligase targeting ligand through a w

296 Combinations of DNMT inhibitors with anti-TIGIT or anti-KLRG1 antibodies furt

297 scovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family su

298 d cause an increasing ratio of activators to inhibitors with size, triggering cell-cycle entry.

299 safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective B

300 r agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, with the risk of Parkinson's disease of user